戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 he chances of full recovery in patients with Bell's palsy.
2 of antiviral medications in the treatment of Bell's palsy.
3  a beneficial role in select cases of severe Bell's palsy.
4 es (e.g., reactivation of herpes simplex) of Bell's palsy.
5 1.31) were independent predictors of risk of Bell's palsy.
6  4 transaminitis and a second had reversible Bell's palsy.
7 at certain vaccines may increase the risk of Bell's palsy.
8  a knowledge of the clinical presentation of Bell's palsy.
9 lished guidelines for the acute treatment of Bell's palsy advocate for steroid monotherapy, although
10 ber 1999, there were 1,181 incident cases of Bell's palsy among US service members.
11 blished studies on the medical management of Bell's palsy and highlight strategies in the surgical ma
12  resemble the clinical signs associated with Bell's Palsy and Moebius Syndrome in humans.
13 proven to be efficacious in the treatment of Bell's palsy and should be offered to patients presentin
14 costeroids has been shown to be effective in Bell's palsy, and antibiotics improve the outcome in LNB
15  field loss, trigeminal neuralgia, recurrent Bell's palsy, and pulsatile tinnitus.
16                                              Bell's palsy (BP) is an acute and idiopathic paralysis o
17 l facial palsy (LNB PFP) and idiopathic PFP, Bell's palsy (BP), are the most common causes of facial
18 stages of idiopathic facial paralysis (i.e., Bell's palsy), but their effectiveness is uncertain.
19 potential contributors to the development of Bell's palsy, but the precise cause remains unclear.
20 , or any vaccine (all vaccines combined) and Bell's palsy (definite and probable cases combined).
21 rends, and demographic correlates of risk of Bell's palsy during a 2-year period.
22                             In patients with Bell's palsy, early treatment with prednisolone signific
23                         An increased risk of Bell's palsy, encephalomyelitis, and Guillain-Barre synd
24 sistent with expected (background) rates for Bell's palsy, encephalomyelitis, and Guillain-Barre synd
25 d the immune mediated neurological events of Bell's palsy, encephalomyelitis, Guillain-Barre syndrome
26                   Outcomes were incidence of Bell's palsy, encephalomyelitis, Guillain-Barre syndrome
27 rapy have been proposed for the treatment of Bell's palsy for many years, the clinical efficacy of th
28 ontrolled case series was conducted only for Bell's palsy, given limited statistical power, but with
29 15-3.92 at 15-21 days after vaccination) and Bell's palsy (IRR, 1.29; 95% CI: 1.08-1.56 at 15-21 days
30                                              Bell's palsy is a common cranial neuropathy causing acut
31                                              Bell's palsy is a relatively common disease characterize
32                                              Bell's palsy is more prevalent in women who are either p
33 thrombosis, pulmonary embolism, anaphylaxis, Bell's palsy, myocarditis or pericarditis, narcolepsy, a
34 rofile associated with humans suffering from Bell's Palsy or Moebius Syndrome.
35 herpes zoster and 1 DZB(-)MMF(+) subject had Bell's palsy possibly related to VZV.
36 e representation of a new mother affected by Bell's palsy subsequent to her recent pregnancy.
37 ulopathy, multisystem inflammatory syndrome, Bell's palsy, transverse myelitis, appendicitis, pulmona
38 the UK, the standardised incidence ratio for Bell's palsy was 1.33 (1.02 to 1.74), for encephalomyeli
39 zed, factorial trial involving patients with Bell's palsy who were recruited within 72 hours after th